CF
JANX icon

Corebridge Financial’s Janux Therapeutics JANX Stock Holding History

Corebridge Financial’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-15,495
Closed -$418K – 1389
2025
Q1 		$418K Buy
15,495
+1,555
+11% +$58.6K ﹤0.01% 1691
2024
Q4 		$746K Sell
13,940
-1,053
-7% -$55.7K ﹤0.01% 1470
2024
Q3 		$681K Sell
14,993
-92
-0.6% -$4K ﹤0.01% 1565
2024
Q2 		$632K Buy
+15,085
New +$708K ﹤0.01% 1566

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Corebridge Financial's JANX Position: Q2 2025 in Review

Corebridge Financial sold out of Janux Therapeutics (JANX) in Q2 2025, closing a stake of 15,495 shares — an estimated $418K sold.

Corebridge Financial first reported a position in JANX in Q2 2024 and held it in 4 quarters. The position peaked at $746K in Q4 2024. 174 funds tracked by Wall St. Rank hold JANX as of Q2 2025.

  • Corebridge Financial reported no remaining Janux Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 15,495 Janux Therapeutics shares in Q2 2025, an estimated $418K.
  • Corebridge Financial first reported a position in Janux Therapeutics in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Janux Therapeutics position peaked at $746K in Q4 2024.
  • 174 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.